Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1979 1
1983 1
1984 1
1985 1
1988 1
1989 2
1990 1
1992 2
1994 2
1995 1
1996 1
1997 3
1999 2
2000 1
2002 1
2004 2
2006 2
2007 2
2008 1
2009 1
2010 4
2011 3
2012 5
2013 2
2014 4
2015 1
2016 1
2017 3
2018 5
2019 3
2020 2
2021 8
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
Chiorean EG, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Chiorean EG, et al. J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. doi: 10.6004/jnccn.2023.0034. J Natl Compr Canc Netw. 2023. PMID: 37433437
Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used …
Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first- …
Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Vanbiervliet G, Strijker M, Arvanitakis M, Aelvoet A, Arnelo U, Beyna T, Busch O, Deprez PH, Kunovsky L, Larghi A, Manes G, Moss A, Napoleon B, Nayar M, Pérez-Cuadrado-Robles E, Seewald S, Barthet M, van Hooft JE. Vanbiervliet G, et al. Endoscopy. 2021 Apr;53(4):429-448. doi: 10.1055/a-1397-3198. Epub 2021 Mar 16. Endoscopy. 2021. PMID: 33728632 Free article.
1: ESGE recommends against diagnostic/therapeutic papillectomy when adenoma is not proven.Strong recommendation, low quality evidence. 2: ESGE recommends endoscopic ultrasound and abdominal magnetic resonance cholangiopancreatography (MRCP) for staging of ampullary tumors. …
1: ESGE recommends against diagnostic/therapeutic papillectomy when adenoma is not proven.Strong recommendation, low quality evidence …
Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies.
Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, Massironi S. Rossi RE, et al. World J Gastroenterol. 2021 Sep 21;27(35):5890-5907. doi: 10.3748/wjg.v27.i35.5890. World J Gastroenterol. 2021. PMID: 34629807 Free PMC article. Review.
Zollinger-Ellison syndrome (ZES) associated with pancreatic or duodenal gastrinoma is characterized by gastric acid hypersecretion, which typically leads to gastroesophageal reflux disease, recurrent peptic ulcers, and chronic diarrhea. ...Herein, we reviewed availa …
Zollinger-Ellison syndrome (ZES) associated with pancreatic or duodenal gastrinoma is characterized by gastric acid hypersecretion, w …
Management and Prognosis of Localized Duodenal Neuroendocrine Neoplasms.
Gay-Chevallier S, de Mestier L, Perinel J, Forestier J, Hervieu V, Ruszniewski P, Millot I, Valette PJ, Pioche M, Lombard-Bohas C, Subtil F, Adham M, Walter T. Gay-Chevallier S, et al. Neuroendocrinology. 2021;111(8):718-727. doi: 10.1159/000508102. Epub 2020 Apr 24. Neuroendocrinology. 2021. PMID: 32335556
INTRODUCTION: The characteristics, prognostic factors, and management of duodenal neuroendocrine neoplasms (dNEN) are ill-defined, given their rarity. ...METHODS: All consecutive patients with nonmetastatic dNEN managed between 1981 and 2018 in 2 expert centers were …
INTRODUCTION: The characteristics, prognostic factors, and management of duodenal neuroendocrine neoplasms (dNEN) are ill-defi …
Clinical Characteristics and Endoscopic Management of Duodenal Lipomas: 10-Year Experience from a Tertiary Center in China.
Xiang J, Chai N, Li L, Xu N, Wang P, Cheng Y, Linghu E. Xiang J, et al. Turk J Gastroenterol. 2023 Jul;34(7):720-727. doi: 10.5152/tjg.2023.22617. Turk J Gastroenterol. 2023. PMID: 37326152 Free PMC article.
There remained issues about the understanding and management of duodenal lipomas to be clarified. We aimed to investigate the clinical and endoscopic features of duodenal lipomas. ...The rate of en bloc and endoscopic complete resection was 93.1% and 86.2%, respecti …
There remained issues about the understanding and management of duodenal lipomas to be clarified. We aimed to investigate the clinica …
Treatment of gastric ulcer. What is old and what is new.
Lewis JH. Lewis JH. Arch Intern Med. 1983 Feb;143(2):264-74. Arch Intern Med. 1983. PMID: 6337574 Review.
The rational treatment of gastric ulcer (GU) requires both an understanding of the various causative factors responsible for what is best considered a spectrum of disorders, as well as a familiarity with the newer antisecretory and cytoprotective therapies that are availab …
The rational treatment of gastric ulcer (GU) requires both an understanding of the various causative factors responsible for what is best co …
Endoscopic management of superficial nonampullary duodenal tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Vanbiervliet G, Moss A, Arvanitakis M, Arnelo U, Beyna T, Busch O, Deprez PH, Kunovsky L, Larghi A, Manes G, Napoleon B, Nalankilli K, Nayar M, Pérez-Cuadrado-Robles E, Seewald S, Strijker M, Barthet M, van Hooft JE. Vanbiervliet G, et al. Endoscopy. 2021 May;53(5):522-534. doi: 10.1055/a-1442-2395. Epub 2021 Apr 1. Endoscopy. 2021. PMID: 33822331 Free article.
1: ESGE recommends that all duodenal adenomas should be considered for endoscopic resection as progression to invasive carcinoma is highly likely.Strong recommendation, low quality evidence. 2: ESGE recommends performance of a colonoscopy, if that has not yet been done, in …
1: ESGE recommends that all duodenal adenomas should be considered for endoscopic resection as progression to invasive carcinoma is h …
Update on Helicobacter pylori treatment.
Ables AZ, Simon I, Melton ER. Ables AZ, et al. Am Fam Physician. 2007 Feb 1;75(3):351-8. Am Fam Physician. 2007. PMID: 17304866 Free article. Review.
Although it is unclear whether eradication of H. pylori improves symptoms in patients with nonulcer dyspepsia, there is strong evidence that eradication of this bacteria improves healing and reduces the risk of recurrence or rebleeding in patients with duodenal or g …
Although it is unclear whether eradication of H. pylori improves symptoms in patients with nonulcer dyspepsia, there is strong evidence that …
Treatment of malignant gastric outlet obstruction with endoscopically placed self-expandable metal stents.
Gaidos JK, Draganov PV. Gaidos JK, et al. World J Gastroenterol. 2009 Sep 21;15(35):4365-71. doi: 10.3748/wjg.15.4365. World J Gastroenterol. 2009. PMID: 19764086 Free PMC article. Review.
Malignant gastroduodenal obstruction can occur in up to 20% of patients with primary pancreatic, gastric or duodenal carcinomas. ...Both endoscopic stenting and surgical bypass are considered palliative treatments and, to date, no improvement in survival with either …
Malignant gastroduodenal obstruction can occur in up to 20% of patients with primary pancreatic, gastric or duodenal carcinoma …
The Characteristics and Treatment Outcomes of 71 Duodenal Brunner's Gland Adenomas with Endoscopic Submucosal Dissection.
Xiang Y, Liu J, Wang NY, Tang D, Wang L, Zou PX, Xu G, Huang Q. Xiang Y, et al. Dig Dis. 2023;41(6):852-859. doi: 10.1159/000531231. Epub 2023 Aug 17. Dig Dis. 2023. PMID: 37591214
INTRODUCTION: The aim of this study was to investigate outcomes of patients with duodenal Brunner's gland adenomas (BGAs) that were treated endoscopically. ...CONCLUSION: ESD was an effective and safe therapeutic option for BGA patients with excellent outcomes. Long …
INTRODUCTION: The aim of this study was to investigate outcomes of patients with duodenal Brunner's gland adenomas (BGAs) that were t …
66 results